연구동향 분석
박사

Peroxisome proliferator-activated receptors-delta (PPAR-δ) is associated with liver fibrosis in patients with nonalcoholic fatty liver disease : 비알코올성 지방간 질환에서 간섬유화의 진행과 Peroxisome proliferator-activated receptors-delta (PPAR-δ) 의 발현과의 연관성

권오성 2019년

논문상세정보
인용/피인용
' Peroxisome proliferator-activated receptors-delta (PPAR-δ) is associated with liver fibrosis in patients with nonalcoholic fatty liver disease : 비알코올성 지방간 질환에서 간섬유화의 진행과 Peroxisome proliferator-activated receptors-delta (PPAR-δ) 의 발현과의 연관성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 질병
  • Liver fibrosis
  • nafld
  • pparδ
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
155 0

0.0%

' Peroxisome proliferator-activated receptors-delta (PPAR-δ) is associated with liver fibrosis in patients with nonalcoholic fatty liver disease : 비알코올성 지방간 질환에서 간섬유화의 진행과 Peroxisome proliferator-activated receptors-delta (PPAR-δ) 의 발현과의 연관성' 의 참고문헌

  • Zardi EM, Navarini L, Sambataro G, et al. Hepatic PPARs: their role in liver physiology, fibrosis and treatment. Curr Med Chem. 2013;20(27):3370-3396.
  • Stanciu A, Floarea-Strat A. [Knodell and Metavir scoring systems--advantages and limits]. Rev Med Chir Soc Med Nat Iasi. 2002;106(4):753-756.
  • Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359-365.
  • Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol. 2015;7(8):1012-1019.
  • Smedsrod B, Pertoft H, Gustafson S, Laurent TC. Scavenger functions of the liver endothelial cell. Biochem J. 1990;266(2):313-327.
  • Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76.
  • Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferatoractivated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-339.
  • Pang M, de la Monte SM, Longato L, et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol. 2009;50(6):1192-1201.
  • Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol. 2006;536(1- 2):182-191.
  • Lee HJ, Yeon JE, Ko EJ, et al. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21(45):12787-12799.
  • Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci U S A. 2012;109(21):E1369-1376.
  • Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 2005;10(5):927-939.
  • Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428.
  • De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des. 2013;19(29):5239-5249.
  • Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2(12):1048- 1058.
  • Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31(1):241-246.
  • Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-8.
  • Bays HE, Schwartz S, Littlejohn T, 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96(9):2889-2897.
  • Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65(6 Pt 2):S57-63.